Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the CRYSTAL study – a phase I/II clinical trial protocol

Maria Alessia Zerella¹, Mattia Zaffaroni¹, Giuseppe Ronci², Samantha Dicuonzo¹, Damaris Patricia Rojas¹, Anna Morra¹, Cristiana Fodor¹, Elena Rondi², Sabrina Vigorito², Francesca Botta², Marta Cremonesi³, Cristina Garibaldi³, Silvia Penco⁴, Viviana Enrica Galimberti⁵, Mattia Intra⁶, Sara Gandini⁶, Massimo Barberis⁷, Giuseppe Renne⁷, Federica Cattani², Paolo Veronesi⁵, Roberto Orecchia⁹, Barbara Alicja Jereczek-Fossa¹,⁸ and Maria Cristina Leonardi¹ *

Abstract

Background: Breast-conserving surgery (BCS) and whole breast radiation therapy (WBRT) are the standard of care for early-stage breast cancer (BC). Based on the observation that most local recurrences occurred near the tumor bed, accelerated partial breast irradiation (APBI), consisting of a higher dose per fraction to the tumor bed over a reduced treatment time, has been gaining ground as an attractive alternative in selected patients with low-risk BC. Although more widely delivered in postoperative setting, preoperative APBI has also been investigated in a limited, though increasing, and number of studies. The aim of this study is to test the feasibility, safety and efficacy of preoperative radiotherapy (RT) in a single fraction for selected BC patients.

Methods: This is a phase I/II, single-arm and open-label single-center clinical trial using CyberKnife. The clinical investigation is supported by a preplanning section which addresses technical and dosimetric issues. The primary endpoint for the phase I study, covering the 1st and 2nd year of the research project, is the identification of the maximum tolerated dose (MTD) which meets a specific target toxicity level (no grade 3–4 toxicity). The primary endpoint for the phase II study (3rd to 5th year) is the evaluation of treatment efficacy measured in terms of pathological complete response rate.

Discussion: The study will investigate the response of BC to the preoperative APBI from different perspectives. While preoperative APBI represents a form of anticipated boost, followed by WBRT, different are the implications for the scientific community. The study may help to identify good responders for whom surgery could be omitted. It is especially appealing for patients unfit for surgery due to advanced age or severe co-morbidities, in addition to or instead of systemic therapies, to ensure long-term local control. Moreover, patients with oligometastatic disease synchronous with primary BC may benefit from APBI on the intact tumor in terms of tumor progression free survival. The study of

*Correspondence: cristina.leonardi@ieo.it
¹ Department of Radiation Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Whole breast radiation therapy (WBRT) after breast-conserving surgery (BCS) is the standard of care for patients with early-stage breast cancer (BC) [1]. Over the last two decades, radiotherapy (RT) for BC has undergone major changes in fractionation, techniques and target volumes [2–4].

Hypofractionation is now considered the preferred schedule for adjuvant WBRT on the basis of the results of dedicated randomized phase III studies showing equivalent tumor control, improved acute toxicity and similar late toxicity rates compared to conventional fractionation [5–7]. Hypofractionation has been successfully applied in the setting of accelerated partial breast irradiation (APBI) where the treatment is given only to the tumor bed as the region at higher risk of relapse [8–10]. A number of APBI phase III trials using different techniques have showed that, in selected patients, APBI achieved a satisfactory local control, comparable with that of WBRT, but with fewer side effects, greater convenience, better quality of life, reduced costs [11–15]. The safety and the efficacy of APBI delivered in postoperative setting have stimulated investigations in the preoperative field as well. In this context, preoperative APBI can be regarded as anticipated boost, followed by WBRT after surgery, or can be used with neoadjuvant purpose, to reduce the size of the lesion allowing more conservative surgery and to test the tumor sensibility. The latter investigation might open to the possibility of a definitive RT with curative intent.

Older and/or frail women that are less likely to receive standard of care treatments, often because of medical comorbidities, might benefit the most [16–18].

The algorithm to replace surgery with RT has proved to be successful in the treatment of oligometastases. Short courses of high dose stereotactic ablative radiosurgery (SRS) have frequently being used as alternatives to surgery for oligometastases. Starting from the benefits observed for solitary brain metastases, the use of SRS has been expanded to include extracranial sites. Scorsetti and coll. [19], considering a cohort of 33 BC oligometastatic patients, observed local control rates of 98 and 90% at 1 and 3 years, with complete and partial response rates of 53 and 34% respectively. These results may provide the rationale to investigate the effect of delivering high-dose single fraction to small primary BC.

The feasibility and the efficacy of a pre-operative radioablation approach on primary BC have been investigated in few clinical studies, using different technique, dose/fraction, number of fractions, total dose and irradiated volumes. Preliminary reports demonstrate low toxicity and a rate of pathological response worthwhile exploring further [20–27].

The aim of the present study is to test the feasibility, safety and efficacy of preoperative RT in a single fraction for selected BC patients.

Methods/design
Aim, design, and setting of the study
This is a monocentric phase I/II, single-arm and open-label trial planning to enroll a maximum of 79 patients over 5 years and using CyberKnife to deliver the ablative dose (18–24 Gy) to the tumor before surgery. The clinical investigation includes a preplanning section in which technical issues (contouring, set-up, dosimetry, treatment delivery, etc.) are addressed. The project was registered at clinicaltrials.gov (NCT04679454) and was approved by institutional Ethical Committee (identification number 1308).

Study population
Participant characteristics and eligibility criteria
Inclusion and exclusion criteria are summarized in Table 1.

After study enrollment, a core biopsy is performed for tumor characterization. At the time of core biopsy, at least 3 gold fiducial markers, of 1 mm × 1.5 mm size and compatible with any radiologic examinations, are placed around the tumor under ultrasound guidance for RT target localization along the 3 axes.

Radiological work-up is completed with preoperative magnetic resonance imaging (MRI) in supine and prone position.

Study design
The research project comprises 6 tasks:

1. Technological assessment – a pre-clinical investigation of radioablation feasibility using CyberKnife is conducted to establish protocol procedures;
2. Patients enrollment and monitoring - patients are enrolled according to the inclusion criteria. Maximum acute toxicity at 1 and 2 weeks after radioablation is evaluated to modulate the accrual throughout the phase I dose escalation study;

3. Histopathologic analysis - tumor characteristics and radiation response are investigated through histopathologic analyses of biopsy and surgical specimen;

4. Radiology and Radiomics tasks - imaging features extracted from pre- and post- radioablation MRI are quantitatively and semi-quantitatively analyzed to identify imaging markers of radiation response;

5. Molecular pathology – expression of genes involved in tumor–immune system interactions is analyzed through next generation sequencing (NGS) assays.

| Table 1 | Inclusion and exclusion criteria |
|-----------------|-----------------------------|
| **ELIGIBILITY CRITERIA** | **INCLUSION CRITERIA** |
| | Histologically proven unifocal adenocarcinoma of breast cancer |
| | cT1–cT2 cN0 |
| | Age ≥ 18 years old |
| | Good general condition (ECOG 0–2) |
| | Planned surgery (BCS or mastectomy) |
| | Written informed consent |
| | Tumor too close to skin or chest wall |
| | Pure non-invasive tumor |
| | Prior RT to the chest |
| | Neoadjuvant chemotherapy |
| | Coagulation, connective, autoimmunitary disorders |
| | Previous malignancies |
| **EXCLUSION CRITERIA** | |
| Tumor too close to skin or chest wall | |
| Pure non-invasive tumor | |
| Prior RT to the chest | |
| Neoadjuvant chemotherapy | |
| Coagulation, connective, autoimmunitary disorders | |
| Previous malignancies | |

List of abbreviations: BCS breast conserving surgery, ECOG Eastern Cooperative Oncology Group, RT radiotherapy

Phase I study
Dose escalation is designed as a traditional 3 + 3 rule-based study. This study design is the prevailing method for conducting phase I cancer clinical trials since it avoids the selection of phase II doses that cause a treatment-limiting toxicity in more than 17% of subjects [28]. This rule-based design proceeds with cohorts of three patients testing three dose levels: 18 Gy, 21 Gy and 24 Gy. Starting from the lowest prescription dose, if none of the three patients in the first cohort experiences a dose limiting toxicity (DLT), other three patients will be treated at the next dose level. However, if one of the first three patients experiences a DLT, three more patients will be treated at the same dose level. The dose escalation continues up to the 24 Gy dose level until at least 2 patients among a cohort of 3 to 6 patients experience DLT. The recommended dose for subsequent phase II trial is defined as the dose level just below this toxic value. Maximum tolerated dose (MTD) is decided when 6 patients are treated at a dose level and a maximum of 1 out of 6 (17%) patients experiences DLT. The starting dose level of 18 Gy is considered to be safe based on the basis of previous studies [22]. Phase I study will enroll a maximum of 18 patients, depending on the number of dose level escalations and the number of DLTs observed.

Phase II study
The recommended dose level found in the first phase will be delivered in the phase II study. The primary endpoint of the phase II study is the rate of pathological complete response (pCR). In the current research project, radioablation is expected to be as effective as a single drug agent. A pCR rate of 20% is chosen to test the efficacy of radioablation.

A study requires 61 patients to decide whether the proportion of responders, i.e. $P$, is $\leq 9\%$ or $\geq 20\%$. If the number of responses is 10 or more, the hypothesis that $P \leq 9\%$ is rejected with a target error rate of 5%. If the number of responses is 9 or less, the hypothesis that $P \geq 20\%$ is rejected. Therefore, in the projected population of 61 patients, at least 10 patients with pCR are required to reject the null hypothesis of no treatment efficacy.

Treatment planning
The preoperative MRI is acquired in prone position for diagnostic purpose to exclude multicentricity. With the aim of improving target definition and tumor tracking during treatment, a preoperative MRI with fiducial markers in place in supine position is used for rigid and/or deformable registration with treatment planning non-contrast computed tomography (CT) images.

Gross tumor volume (GTV) is contoured by a radiation oncologist and then double-checked by a second radiation oncologist. The GTV is expanded by 0.5 cm to
create the clinical tumor volume (CTV) which coincides with planning tumor volume (PTV). Plans are elaborated on the Cyberknife Treatment Planning System (Precision, Accuray), using a non-coplanar and non-isocentric approach. Treatment delivery was carried out using a real-time fiducial-based target tracking (Synchrony®); the total system accuracy of the Robotic stereotactic radioablation/motion tracking has been reported as < 1 mm [29–31], which allowed the use of much smaller margins compared with conventional radiosurgery and therapy methods.

Pre-specified dose constraints for organs at risk and planning objectives for target are based on the National Surgical Adjuvant Breast and Bowel Project B-39/Radiation Therapy Oncology Group 0413 partial breast trial [32] and on stereotactic radiosurgery [33].

Further optimization of dosimetric parameters will be done as the study proceeds.

Treatment
Radioablation is performed within 4 weeks since patient entering the study and no systemic therapy is allowed in the pre-operative settings.

Surgical tumor removal is scheduled within 8 weeks from radioablation.

All patients receive postoperative RT without boost to the tumor bed, preferably with hypofractionation (preferably, 2.67 Gy × 15 fractions). Systemic therapy is administered according to the institutional guidelines.

Post-surgical complications as well as radiation side effects are collected and follow-up is scheduled on regular basis throughout 3 years.

An overview of the treatment workflow is reported in Fig. 1.

Endpoints of the study
Phase I endpoints
Primary endpoint of the phase I study is to identify MTD, which is the dose that meets a specific target toxicity level (no grade (G) 3–4 toxicity).

Outcome measures is obtained through acute skin/soft tissue toxicity, measured according to NCI CTCAE v. 4.03 [34]. Any G3–4 toxicity related to radioablation is considered dose limiting (DLT).

Secondary endpoints include chronic toxicity, cosmesis, post-surgery complications, outcomes of survival and relapse, extra-cutaneous complications and pCR.
**Phase II endpoints**

Primary endpoint is the evaluation of the efficacy measured in terms of pCR rate.

Outcome measures is obtained through the pCR rate after surgery, according to the Modified Residual Cancer Burden (RCB) index.

Secondary endpoints include acute/chronic toxicity, cosmesis, post-surgery complications, outcomes of survival and relapse, extra-cutaneous complications.

**Ethical aspects**

The study is conducted according to the Declaration of Helsinki/Tokyo and to Good Clinical Practice guidelines.

The protocol has been presented to and approved by the ethics committee of the European Institute of Oncology IRCCS, Milan. After complete explanation of the objectives and modalities of the study, each patient is required to give written informed consent for participation in the study.

**Discussion**

A broader knowledge and better understanding of BC biology along with advances in RT planning, targeting, and delivery, have changed the attitude towards BC treatments, with the abandonment of the concept of “one size fits all” in favor of approaches more tailored on the tumor and on the individual. Escalation and de-escalation of RT dose and target volumes, as well as RT omission, must be weighed up at the cost-benefit analysis. This approach expresses the modern concept of high-precision medicine where decision-making is processed at a multidisciplinary level, in accordance to the biologic aggressiveness of the disease, the radiosensitivity, the expected pattern of relapse and the integration with systemic therapies.

More recently, the hypothesis to anticipate RT before surgery has become a growing area of investigation. Preoperative RT is not a new concept in itself, as early experiences date back to the '70s. However, the historical approach typically encompassed the whole breast and the regional nodal drainage and the extension of the RT fields drew some concerns regarding the increase of surgical complications [35]. Therefore, preoperative RT fell out of use as the neoadjuvant systemic therapy was gaining ground. With the introduction and affirmation of APBI, which in the postoperative setting has been proven to be an acceptable alternative to WBRT in properly selected patients [11–15, 32, 33], the interest for preoperative RT has grown again. Preoperative APBI carries a number of advantages compared to postoperative APBI [36]. By irradiating an intact lesion with an image-guided approach, issues related to treatment volume delineation are minimized, decreasing inter-observer contouring variability and improving target volume definition thanks to the co-registration of MRI with simulation CT images. As the target corresponds to the tumor rather than to a large postoperative area, the irradiation of uninvolved breast tissues is significantly reduced, allowing ultrahypofractionated schedules and further shortening RT duration. In addition, as consequence of cytotoxic effect, the tumor may shrink, reducing the amount of normal tissue to be removed during the surgery. The combination of more conservative surgery and smaller irradiated volume might result in milder breast fibrosis and in an overall better cosmesis. Moreover, preoperative APBI provides the possibility to test the radio-sensitivity analyzing tumor changes at molecular and genomic levels. These data can ideally be employed to build a classifier to stratify class of responders and non-responders, contributing to a better understanding of radiobiologic effects and behavior of the irradiated tumors [23] in a wider view of personalized medicine. Also MRI quantitative parameters collected in pre- and post- radiation setting could potentially be applied as radiation response biomarkers [37] and prognostic/predictive tools [38]. Researchers at the Duke Cancer Institute [22] extensively investigated the effect of preoperative single fraction RT in the field of imaging and gene expression and found an increase in vascular permeability and a decrease of cellular density after radioablation in MRI images. The current study provides the opportunity to compare pre- and post- radioablation MRI images in order to assess radiological tumor response and identify imaging biomarkers of radiation response through qualitative and semiquantitative analysis. The ultimate goal is to identify those tumors which achieve complete response and that may remain in control without the need of being surgically removed.

As observed for postoperative APBI, different techniques have been used to perform preoperative APBI: three-dimensional conformal RT (3D-CRT), intensity modulated RT (IMRT), volumetric-modulated arc-therapy (VMAT), SRS and stereotactic body RT (SBRT), brachytherapy (BRT) and proton beam therapy (PBT) [39–43]. Main preoperative APBI studies published in the literature are summarized in Table 2, while Table 3 and Table 4 describe the ongoing clinical trials. Because of the complexity of BRT and the requirement of a larger PTV for 3DCRT/IMRT, stereotactic techniques are preferred for preoperative approach to BC, given their proven efficacy and safety in the treatment of a great variety of primary and metastatic tumors [44–47]. In the current study, single fraction preoperative radioablation is investigated using robotic SBRT with CyberKnife system, which allows smaller margins, less radiation exposure to adjacent normal tissue and, potentially, better cosmetic outcomes. Moreover, Cyberknife is capable of tracking the target volume...
Table 2 Summary of the studies on preoperative breast cancer radiotherapy

| Author and year | Inclusion criteria | n of pts | Treatment | Systemic therapy | Time to surgery | Postoperative RT | Outcomes | Toxicity | Follow-up (months) |
|-----------------|--------------------|----------|-----------|------------------|-----------------|-----------------|----------|----------|-------------------|
| Bondiau et al., 2013 [21] | Unifocal BC not suitable for BCS, HER2 negative | 26 | Robotic SBRT (Cyberknife)/19.5-31.5 Gy/3 fr (5 dose levels) | CHT | 4-8 weeks after last CHT | Yes, 3D-CRT | pCR 36% (NS) 92% BCS rate 96% ORR | none | 30 |
| Horton et al., 2015 [22] | Age > 55 years, T1 BC or low-intermediate DCIS ≤ 2 cm, cN0, ER+ and/or PR+, HER2- | 32 | IMRT/1.5–21 Gy (3 dose levels)/1 fr | none | within 10 days after RT | Yes (Only to patients not satisfying eligibility criteria after BCS) | Significant increase in MRI post-radiation vascular permeability and decreased cellular density | 13 Grade 2; 2 Grade 3 | 23 |
| van der Leij et al., 2015 [23] | Age > 60 years, invasive, unifocal BC ≤ 3 cm on MRI, non-lobular, negative SNB | 70 | 3D-CRT or IMRT or VMAT/40 Gy/10 fr | none | 6 weeks after RT | No | 2 local recurrences | 11% mild-moderate 23 induration at 12 months; 2% mild-moderate fibrosis at 24 months | 23 |
| Nichols et al., 2017 [24] | Unifocal invasive BC ≤ 3 cm at mammography or MRI, cN0 | 27 | 3D-CRT /38.5 Gy/10 fr (twice daily) | none | > 21 days after RT | No | pCR 15% (NS) ORR 88.9% Ki-67 reduction after RT in 70.4% | PRCO fair and poor in 17 and 5% at 1 year, respectively | 43 |
| Tiberi et al., 2020 [27] | postmenopausal status, age > 65 years, stage I (T1N0) invasive BC, unifocal luminal A, ER+, her2-negative, G1–2 | 10 | SBRT 20Gy/1fr | none | 11–13 weeks after RT | Yes if. Grade 3, lymphovascular invasion, pT4, triple neg, extensive DCIS, tumor size > 3 cm, lobular histology | pCR 0 (median residual cellularity was 3% in 8 patients; for the other 2 patients no response at all was observed) | none | < 12 |

DOSIMETRIC STUDIES

| Author and year | Inclusion criteria | n of pts | Treatment | Systemic therapy | Time to surgery | Postoperative RT | Outcomes | Toxicity | Follow-up (months) |
|-----------------|--------------------|----------|-----------|------------------|-----------------|-----------------|----------|----------|-------------------|
| Charaghvandi et al., 2015 | Tumor size up to 30 mm, scheduled for BCS and WBI | 20 | IMB and VMAT 15 Gy/1 fr + integrated ablative boost of 20Gy | none | – | – | Dosimetrically feasible with IMB and VMAT | – | – |
| Yoo et al., 2015 [44] | Patients enrolled on a preoperative, dose escalation, single fraction PBI clinical protocol | 16 (8 + 8) | 3D-CRT, non-coplanar IMRT, coplanar IMRT, VMAT 15 Gy/1 fr and 18Gy/1 fr | none | – | – | IMRT plans provided homogeneous and conformal target coverage, skin sparing, and short delivery time | – | – |

List of abbreviations: 3D-CRT 3D conformal RT, BC breast cancer, BCS breast conserving surgery, CHT chemotherapy, CTV clinical target volume, DCIS ductal carcinoma in situ, FX fraction, IMB interstitial multicatheter brachytherapy, IMRT intensity modulated RT, MRI magnetic resonance imaging, PBI partial breast irradiation, pCR pathological complete response, RT radiotherapy, SBRT stereotactic body radiotherapy, VMAT volumetric modulated arc therapy, ER estrogen, PR progesterone, HER2 human epidermal growth factor receptor 2, SNB sentinel node biopsy, NS not statistically significant, ORR objective response rate, PRCO patient reported cosmetic outcome
Table 3  Summary of the clinical trials regarding pre-operative breast cancer radiotherapy in more than one fraction

| Trial ID     | Status    | Title                                                                 | Treatment                                                                 | Description/endpoint                                                                 | Primary outcome measure                                                                 | Estimated/actual primary completion date       |
|-------------|-----------|----------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------|
| NCT04360330 | Recruiting| SABER study for selected early-stage BC                               | Stereotactic Ablative RT RT dose: 4 predefined dose levels (35 Gy, 40 Gy, 45 Gy, 50 Gy in 5 fractions given on non-consecutive days, over a period of 2 weeks). Then standard of care surgery. | Find the most effective RT dose to give to BC in a shorter period of time, prior to surgery. Toxicity, cosmesis and quality of life will be assessed. | Find the recommended Phase 2 Dose of Pre-Operative SABER in terms of the highest dose level tested for which no more than 1 out of 6 patients experience DLT | August 2023                                   |
| NCT04234386 | Recruiting| GammaPod Dose Escalation RT for early-stage BC                        | GammaPod Radiation RT dose: 4 predefined dose levels (21 Gy, 24 Gy, 27 Gy, 30 Gy). Then standard of care surgery. | Determine a safe and effective dose of pre-operative RT to treat early stage BC. Cosmesis and quality of life will be assessed. | Establish the single-fraction MTD and DLTs                                                | December 2025                                 |
| NCT03624478 | Recruiting| Hypofractionated RT in Treating Participants with BC before surgery   | Hypofractionated RT RT dose: NS (5 consecutive days followed by standard of care surgery). | Assess the efficacy, toxicity, pCR cosmetic outcome and pathologic changes of hypofractionated RT in treating breast cancer before surgery (phase II trial) |                                                                                                                                                     | August 17, 2021                               |
| NCT03043794 | Recruiting| Study of Stereotactic RT for BC                                       | Stereotactic RT RT dose: 21 Gy followed by standard of care surgery.      | Assess the efficacy, toxicity, cosmetic outcome, quality of life, and translational correlates to preoperative stereotactic RT for low risk BC (phase II trial) | pCR                                                                                      | August 1, 2022                                |

*List of abbreviations: BC breast cancer; RT radiotherapy; MTD maximum tolerated dose; DLT dose limiting toxicity; pCR pathological complete response; NS not stated*
### Table 4: Summary of the clinical trials regarding pre-operative breast cancer radiotherapy in single fraction

| Trial ID        | Status       | Title                                                                 | Treatment                                                                 | Description/endpoint                                                                 | Primary outcome measure | Estimated/actual primary completion date |
|-----------------|--------------|-----------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------|------------------------------------------|
| NCT03863301     | Recruiting   | MRI-guided single dose preoperative RT in low-risk BC                 | MR-guided single dose preoperative PBI<br>Dose: a single dose of 20 Gy to GTV and 15 Gy to CTV (GTV + 20mm margin). Breast conserving surgery will be performed 12 months following PBI. | Evaluate efficacy of the treatment 12 months after RT, and to collect data on response monitoring (MRI, liquid biopsies and biopsy of the irradiated tumor). Patient-reported outcome measures will be evaluated. | pCR                     | November 2022                            |
| NCT02482376     | Recruiting   | Preoperative single-fraction RT in early-stage BC                     | Stereotactic body RT<br>Dose: a single fraction of 21 Gy. Then standard of care surgery. | Assess toxicity, efficacy and to provide an avenue for understanding breast cancer radiation response through pre- and post-radiation breast tumor samples | Physician reported rates of good/excellent cosmesis at baseline and 6 months, 1, 2, and 3 years post-treatment as measured by the NRG cosmesis scale | September 2021                          |
| NCT03520894     | Recruiting   | RT in preoperative setting with CyberKnife for BC                     | Single fraction of RT with CyberKnife<br>Dose: a single fraction of 21 Gy. | Evaluate the safety and feasibility of single fraction RT and to identify predictive factors for outcome based on biologic and clinical parameters | Rate of acute skin toxicity events, measured according to RTOG/EORTC scale | May 1, 2022                              |
| NCT01717261     | Recruiting   | Single Pre-Operative RT (SPORT) for low-risk BC                      | Single fraction Pre-Operative RT<br>Dose: Dose escalation (15 Gy, 18Gy, 20Gy). | Assess if RT administered in a single preoperative fraction is tolerable in terms of acute, chronic toxicity and cosmetic outcome. Ipsilateral BC recurrence at 5 years will be assessed. | Acute toxicity and wound healing complications from the preoperative radiation treatment as per NCI CTCAE Common Toxicity Scale. | December 2019                            |
| NCT02316561     | Completed    | Single Dose Ablative RT for Early-Stage BC                           | Single dose ablative PBI<br>Dose: NS. Surgery will be performed 6 months after the ablative RT. | Investigate the feasibility, efficacy, cosmetic results, and quality of life after single dose, ablative PBI. Tumor related genetic characteristics associated with radiotherapy responsiveness will be evaluated. | pCR                     | April 2018, ACTUAL                       |
| NCT02212860     | Recruiting   | Stereotactic Image-Guided Neo-adjuvant Ablative Radiation Then Lumpectomy (SIGNAL) | Stereotactic Body Radiation delivered in prone position, using Volumetric-modulated arc therapy (VMAT), planned on coregistered PET/MRI and CT imaging. Dose: single dose of 21 Gy, then surgery. | Assess toxicity, cosmesis and efficacy of single fraction SBRT in early stage BC. A pathologic assessment of the impact of radiation at a microscopic level and on tumor markers will be performed. | Toxicity graded according to CTCAE 4.0 | April 2018, ACTUAL                       |

List of abbreviations: BC breast cancer, CTV clinical target volume, DLT dose limiting toxicity, GTV gross tumor volume, MR magnetic resonance, MTD maximum tolerated dose, PBI partial breast irradiation, pCR pathological complete response, SBRT stereotactic body radiotherapy, RT radiotherapy, NS not stated, RTOG Radiation Therapy Oncology Group, EORTC European Organisation for Research and Treatment of Cancer, CTCAE Common Terminology Criteria for Adverse Events.
during irradiation to achieve high conformity and dose gradient to the tumor. The current research project plan focuses first on the identification of the maximum tolerated dose, whose efficacy is investigated in terms of pCR rate in the phase II study. The starting dose is 18 Gy in single fraction, which can be considered relatively safe. This dose level was also used by Horton et al. [22] in their phase I dose escalation trial of single-dose preoperative RT for early stage unifocal BC patients. Dose escalation levels were 15 Gy ($n=8$), 18 Gy ($n=8$) or 21 Gy ($n=16$), delivered with IMRT. Post-operative conventional RT was administered to patients not satisfying the eligibility criteria following surgical resection ($n=3$). No dose-limiting toxicity was observed up to 21 Gy and, at a median follow-up of 23 months, no evidence of tumor progression was documented. Physician-rated cosmetic outcomes were good/excellent and chronic toxicities were low in patients receiving preoperative RT only. Among the 3 patients receiving post-operative RT, one with a connective tissue disorder developed two grade 3 chronic toxicities, and one with diabetes suffered from wound infection, while all of them presented a fair/poor cosmetic outcome. Another phase I dose-finding SBRT trial was conducted by Bondiau et al. [21], where 5 dose levels (from 19.5 Gy to 31.5 Gy in 3 fractions) were tested, using a robotic SBRT system during the course of preoperative chemotherapy in locally advanced BC patients. Surgery and conventional post-operative RT were performed 6–8 weeks after neoadjuvant chemoradiotherapy. After observing only one grade 3 toxicity (dermatologic in nature) at 28.5 Gy, the authors concluded that the lower dose of 25.5 Gy in 3 fractions could be used for the phase 2 trial. The French series showed high rate of pCR (36%) and breast-conserving surgery (92%). These excellent results were likely due to the synergic and additive effect of concomitant radiochemotherapy. Relying on RT alone, the rate of pCR is expected to be lower, ranging from 10 to 15%. In the abovementioned series, all patients received WBRT without boost to the tumor bed and none of them presented any excess of toxicity, despite the fact that preoperative APBI was delivered concomitantly with neoadjuvant chemotherapy. This favorable outcome is in contrast to the fair/poor cosmesis of the patients enrolled by Horton and coll., who received both pre- and post-operative RT [22]. Horton and coll. explained such an inconsistency between the 2 series with the presence of comorbidities, affecting the tolerability to the treatment, and with differences in fractionation schedules.

In the Canadian SIGNAL study (NCT02212860) [26] patients received a single 21 Gy fraction with external beam RT (i.e., VMAT) followed by definitive surgery 1 week later. No postoperative RT was planned. At 12 months after surgery toxicity, patient- and physician-rated cosmesis, and quality of life were not significantly different from baseline.

The attractiveness of the single dose has encouraged the start of other investigations, such as the study from the University of Florence (NCT03520894), delivering 21 Gy, with acute skin toxicity as primary endpoint and the one by Tiberi and coll. (NCT03917498) [27], where a dose of 20 Gy is given to the tumor with SBRT. The latter one is followed by BCS after 3 months and by a post-operative moderately hypofractionated WBRT in case of risk factors as G3 tumor, lymphovascular invasion, tumor size ≥3cm, pT4 disease, triple-negative status, lobular histology, or extensive ductal carcinoma in situ (>25% tumor mass). As a matter of fact, the optimal dose has not yet been established and dose-escalation studies continue to be designed. The single dose is currently being investigated in the phase I dose escalation study at the University of Texas Southwestern Medical center (NCT02685332), testing four dose escalation cohorts, 22.5 Gy, 25 Gy, 27.5 Gy and 30 Gy.

So far, there have been two phase II studies, both carried out in in the Netherlands, the Utrecht ABLATIVE study (NCT02316561) [25] and the Amsterdam PAPBI study (NCT01024582). Van Der Leij et al. published a preliminary report of the Amsterdam study [23] where the dose of 40 Gy in 10 daily fractions over 2 weeks was delivered to low risk BC patients with 3D CRT, IMRT or VMAT and no differences among techniques were reported.

The optimal timing to remove the irradiated tumor is another subject of debate. In the available literature (Tables 3 and 4), the RT-surgery interval ranges from 1 week (SIGNAL study) [26] to 6 months (ABLATIVE study) [25], which is still considered acceptable from patient’s perspective. More insights are expected from the ongoing trials, especially from the Canadian SPORT trial (NCT01717261), where low risk BC patients receiving 20 Gy single fraction underwent either immediate surgery (24–72 h after RT, SPORT group) or delayed surgery (11–13 weeks after RT, SPORT-DS [delayed surgery] group). The authors observed a significant decrease in tumor cellularity in SPORT-DS cohort, while no change in cellularity occurred with immediate surgery, but a longer follow-up is needed to determine the prognostic significance of this finding.

Although the results remain limited in terms of number of cases and median follow-up time, the published
data demonstrate the feasibility and the potential of preoperative APBI. Our research project adds to the promising body of literature revolving around the use of stereotactic modality in single fraction in the preoperative setting for early-stage BC patients. The most ambitious goal is to identify radiological, biomolecular or genomic markers able to select good responders to RT for whom surgery could be omitted. Therefore, the preoperative phase is transitional in the development of the ablative treatment algorithm. Once knowledge and expertise have been consolidated, patients unfit for surgery due to advanced age or co-morbidities might be the ideal candidates, with the endpoint of progression free survival. In addition, APBI to the intact tumor might be offered in oligometastatic patients, alongside the treatment of the synchronous distant metastases, in order to treat all the sites of active disease.

Abbreviations
3D-CRT: Three-dimensional conformal RT; APBI: Accelerated partial breast irradiation; BC: Breast cancer; BCS: Breast conserving surgery; BRT: Brachytherapy; C.T: Computed tomography; CTV: Clinical tumor volume; DLT: Dose limiting toxicity; GTV: Gross tumor volume; IMRT: Intensity modulated RT; MRI: Magnetic resonance imaging; MTD: Maximum tolerated dose; NGS: Next generation sequencing; PBT: Proton beam therapy; pCR: Pathological complete response; PTv: Planning tumor volume; RCB: Residual cancer burden; RT: Radiotherapy; SBRT: Stereotactic body RT; SRS: Stereotactic radiosurgery; VMAT: Volumetric-modulated arc-therapy; WBRT: Whole breast RT.

Acknowledgements
The European Institute of Oncology, Milan, Italy is partially supported by the Italian Ministry of Health with Ricerca Corrente and 5% entitled. The authors would like to thank the Associazione Italiana per la Ricerca sul Cancro (AIRC) who supported the study. The Sponsor did not play any role in the study design, collection, analysis and interpretation of data, nor in the writing of the manuscript, nor in the decision to submit the manuscript for publication.

Authors’ contributions
MAZ, MZ, MCL, and BAJF wrote the first draft of the manuscript. SD, DPR, FC, MI, ER and SV wrote sections of the manuscript. GRonci, AM, CF, FB, MIC, CG, SP, VEG, SG, MB, GRenine, PV and RO contributed to manuscript revision, read and approved the submitted version.

Funding
The study has undergone full external peer review and is funded by AIRC under IG 2019 - ID. 23118 project – PI: Leonardi Maria Cristina.

Availability of data and materials
Data of this article will be not available until the final report of this study to avoid bias toward the analysis.

Declarations
Ethics approval and consent to participate
All procedures performed in the present study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. This study has been approved by the Institutional Scientific Board of the European Institute of Oncology (IEO) following a notification to the IEO Ethics Committee (identification number 1308). All participants will sign an informed consent.

Consent for publication
Not applicable.

Competing interests
Maria Cristina Leonardi, Barbara Alcida Jereczek-Fossa and Samantha Dicuonzo received a speaker honorarium from Accuray Inc outside the current work. IEO received a research grant from Accuray Inc entitled “Data collection and analysis of Tomotherapy and CyberKnife breast clinical studies, breast physics studies and prostate study”. Maria Alessia Zerella and Giuseppe Ronci had a research fellowships from AIRC under IG 2019 - ID. 23118 project “Phase I/II clinical trial on single fraction ablative preoperative radiation treatment for early-stage breast cancer”. Mattia Zaffaroni received a research grant by the European Institute of Oncology-Cardiologic Center Monzino Foundation (FIEO-CCM), with a project entitled “Proton therapy vs photon-based IMRT for parotid gland tumors: a model based approach with Normal Tissue Complication Probability (NTCP)” outside the current study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The remaining authors declare no conflicts of interest.

Author details
1Department of Radiation Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy. 2Unit of Medical Physics, IEO, European Institute of Oncology IRCCS, Milan, Italy. 3Department of Radiation Oncology Unit, IRCCS, IEO European Institute of Oncology, Milan, Italy. 4Division of Breast Radiology, IRCCS, IEO European Institute of Oncology, Milan, Italy. 5Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. 6Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. 7Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. 8Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. 9Scientific Directorate, European Institute of Oncology IRCCS, Milan, Italy.

Received: 12 November 2021 Accepted: 16 February 2022
Published online: 02 April 2022

References
1. Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2013;344:e2718. https://doi.org/10.1136/bmj.e2718.
2. Chua BH. Individualised target volume selection and dose prescription after conservative surgery, mastectomy and reconstruction. Breast Edinb Scotl. 2019;48(Suppl 1):S69–75. https://doi.org/10.1016/S0960-9776(19)31128-2.
3. Smith RD, Bentzen SM, Correas OR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81:59–68. https://doi.org/10.1016/j.ijrobp.2010.04.042.
4. Davey I, Rumble RB, Bowen J, Dixon P, Warde P. Members of the IMRT indications expert panel. Intensity-modulated radiotherapy in the treatment of breast cancer. Clin Oncol R Coll Radiol G B. 2012;24:488–98. https://doi.org/10.1016/j.clon.2012.05.003.
5. Whelan TJ, Pignol J-P, Levine MN, Julian JA, Mackenzie R, Papias S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20. https://doi.org/10.1056/NEJMoa0906260.
6. Yamold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2005;75:9–17. https://doi.org/10.1016/j.radonc.2005.01.005.
7. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94. https://doi.org/10.1016/S1470-2045(13)70386-3.
40. Leach MO, Boggis CRM, Dixon AK, Easton DF, Eeles RA, Evans DGR, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARBS). Lancet Lond Engl. 2005;365:1769–78. https://doi.org/10.1016/S0140-6736(05)6481-1.

41. Lightowler SV, Boersma LJ, Fourquet A, Kirola YM, Offerens BV, Poortmans P, et al. Preoperative breast radiotherapy: indications and perspectives. Eur J Cancer Ox Engl. 2017;99(82):184–92. https://doi.org/10.1016/j.ejca.2017.06.014.

42. Palta M, Yoo S, Adamson JD, Prosnitz LR, Horton JK. Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;82:37–42. https://doi.org/10.1016/j.ijrobp.2010.09.041.

43. Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, et al. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res BCR. 2017;19:75. https://doi.org/10.1186/s13058-017-0870-1.

44. Yoo S, Blitzblau R, Yin F-F, Horton JK. Dosimetric comparison of preoperative single-fraction partial breast radiotherapy techniques: 3D CRT, noncoplanar IMRT, coplanar IMRT, and VMAT. J Appl Clin Med Phys. 2015;16:5126. https://doi.org/10.1120/jacmp.v16i1.5126.

45. Blitzblau RC, Arya R, Yoo S, Baker JA, Chang Z, Palta M, et al. A phase 1 trial of preoperative partial breast radiation therapy: patient selection, target delineation, and dose delivery. Pract Radiat Oncol. 2015;5:e513–20. https://doi.org/10.1016/j.prro.2015.02.002.

46. Lischalk JW, Chen H, Repka MC, Campbell LD, Obayomi-Davies Q, Kataria S, et al. Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors. Adv Radiat Oncol. 2018;3:447–57. https://doi.org/10.1016/j.adro.2018.05.002.

47. Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, et al. Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG oncology RTOG 0618 trial. JAMA Oncol. 2018;4:1263–6. https://doi.org/10.1001/jamaoncol.2018.1251.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.